Market Place
Sourcing Support
Onco360 Selected As National Pharmacy Partner For VORANIGO
12 Aug 2024 //
GLOBENEWSWIRE
US FDA approves Servier`s brain tumor treatment
07 Aug 2024 //
PR NEWSWIRE
Agios cashes in on cancer drug again with $905M Royalty Pharma deal
28 May 2024 //
BIOPHARMADIVE
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty
28 May 2024 //
GLOBENEWSWIRE
Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib
21 Feb 2024 //
PR NEWSWIRE
FDA and EMA Accept Vorasidenib Regulatory Submissions for diffuse glioma
20 Feb 2024 //
PR NEWSWIRE
Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib`s Potential
18 Nov 2023 //
PR NEWSWIRE
Vorasidenib Data at SNO Bolster Servier`s Neuro-Oncology Development Program
10 Nov 2023 //
PR NEWSWIRE
Servier Presents Transformational Data from Phase 3 INDIGO Trial of Vorasidenib
04 Jun 2023 //
PR NEWSWIRE
Servier’s $1.8B bet on Agios delivers phase 3 brain tumor win
15 Mar 2023 //
FIERCE BIOTECH
Servier`s PIII INDIGO Trial Investigating vorasidenib Meets Primary Endpoint
14 Mar 2023 //
PR NEWSWIRE
Agios Presents Updated Data from the Ph 1 Dose-escalation Study of Vorasidenib
29 May 2020 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.